This is an aggregated industry headline. Read the full story at PharmaVoice →
The FDA was all in on AI. Will that change?
High-level turnover has introduced uncertainty about how quickly the FDA's agency-wide AI strategy will move forward.
By PharmaVoice
· Jul 24, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the …
The WeekFierceBiotech ↗
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial tea…
The WeekBriefing
Three items stood out this week: U.S. import tariffs on generic drugs, Samsung Biologics pursuing a $1.8 billi…